GOBIOM Use Case 2
Identification of efficacy, response to therapy and drug resistance biomarkers in breast cancer

✓ A drug development team in a big pharmaceutical company working on BCL-2 inhibitors is keen on identifying biomarkers of efficacy, response to therapy and drug resistance in breast cancer.

✓ Once the efficacy biomarkers have been identified the group intends to design effective clinical trials to study the effectiveness of the drug.

✓ Also, identification of response to therapy and resistance biomarkers will aid in identifying right study population for clinical trials.
Identification of qualified and most relevant efficacy biomarkers would aid the group in

✓ Designing effective clinical trials
✓ Reduce biomarker discovery costs
✓ Make informed decisions i.e. crucial Go/no go decisions in drug development
✓ Designing later-phase clinical studies
Identification of qualified and most relevant drug response biomarkers would aid the group in

✓ Stratification of patients who are most likely to respond to treatment
✓ Designing tailor made treatment regimens based on their predicted response
✓ Segregating patients with resistance phenotypes into focused treatment groups